

ReproUnion – Highlighting Sweden and Denmark on the Fertility Map of the World



Professors involved in the project from the Universities of Lund and Copenhagen, from Rigshospitalet and from the Herlev, Bispebjerg and Skåne University hospitals.



“ReproUnion gives us the opportunity to drive science and support research in an area which is of benefit to society”

Per Cantor

Senior Vice President,
Clinical and Non-Clinical R&D

Ferring has embarked upon a unique and exciting journey to boost scientific research in fertility for both men and women. ReproUnion is a key initiative designed to foster research and clinical collaboration across disciplines and geographical borders in fertility. As the sole industry partner, Ferring has committed to funding approximately 10% of the total €15.3 million budget over 3 years. Regional public funding and EU funding will make up the rest.

Central to the ReproUnion philosophy is the desire to optimise the treatment of patients. By combining expertise from different centres, patients can immediately be referred to a specialist either in Sweden or in Denmark.

Professor Aleksander Giwercman, Skåne University Hospital, is one of the initiators of the collaborative initiative. “A combined Swedish-Danish collaboration expands the possibilities for reliable diagnoses and better treatments. Through interaction we are able to achieve even better effect when treating the less common and more specialised fertility diagnoses.”

Joan-Carles Arce, VP Science and Medicine, Reproductive Health at Ferring Pharmaceuticals, is very excited by the research potential this collaboration will generate. “By combining the scientific and clinical knowledge at the universities and hospitals in the region with the strong capabilities and experience in developing

medicinal products at Ferring, there is potential to accelerate activities that address some of the unmet medical needs within the Reproductive Health area.”

Access to clinical experts and patients, as well as technology is essential for clinical research in terms of development of diagnostic and medicinal products. A well coordinated approach to gathering quality data from patients as well as a broad platform for close scientific discussion of the clinical problems, with both established clinicians and new scientists (PhD students), should provide a good basis for clinical progress.

Denmark based Per Cantor, Senior Vice President, Clinical and Non-Clinical R&D, was one of the initial drivers of ReproUnion within Ferring. “ReproUnion gives us the opportunity to drive science and support research in an area which is of benefit to society. Our involvement also sends out a clear signal that we are a serious player in the region.”

With close to 14 years' experience at Ferring, Peter Marcusson, Senior Commercial Director, Nordic Region was instrumental in joining the dots within the company. Understanding both the commercial and the R&D dimensions, he saw ReproUnion as a way to communicate that Ferring is serious about investing in the future. “This type of collaboration will attract interest from researchers from other countries, adding to the pool of expertise in reproductive health in the Nordic area. It's where we want to be with Ferring.”

IPC in Copenhagen is planning to run some of its future clinical Reproductive Health studies through this research network.



Professor Aleksander Giwercman,
Skåne University Hospital